The myAvos app has been designed by behavioral health scientists to set users up for long, healthy lives. Photo via Canva

Meet Laura. She’s not human, but she could be the key to your aging healthfully. She’s the digital wellness coach on myAvos, a groundbreaking app that launched this week from OptiChroniX.

Now meet Le Dam, the woman behind the app. Dam is a medical doctor, as well as CEO and co-founder of OptiChroniX. While practicing medicine in her birthplace of Australia, Dam realized that her life of prescribing medications to patients who were already sick was not how she had envisioned helping people. She knew that prevention, using the five pillars of healthy aging — nutrition, activity, sleep, health, and stress — was the way to keep patients fit and happy into their golden years.

She returned to California, where she lived after leaving Houston as a youth, to work at a startup with the goal of one day heading a company of her own. She met Swiss-based COO and co-founder, Rene Gilvert, on LinkedIn.

“He was looking for a medical doctor to join his startup,” Dam recalls. “We were so well aligned that we decided to join forces.” Now, the team works remotely in locations ranging from Dam’s home in Houston to Portugal.

When the pandemic happened, Dam took the opportunity to leave the Silicon Valley and work remotely from Houston, a return that she says was always her end goal.

“I always knew that I wanted to build my business in Houston,” Dam says, mentioning the assets of the world’s largest medical center, a thriving startup community, and diverse population for whom she wants to build her technology.

myAvos pairs with a user’s smart watch and harnesses their health information such as physical activity and hours slept. The user can also input additional information such as blood test results and meals eaten. The app analyzes the information provided and assesses the user’s risk for chronic illness later in life. From there, Laura coaches them on what changes they can make to live healthier lifestyles. The app even reminds users when to take their medications and shares information with designated caregivers.

The myAvos app has a comprehensive approach to health. Screenshots via avos.health

The app has been designed by behavioral health scientists to understand why you’re not exercising enough or eating right and can offer personalized motivations to get users off the couch.

Right now, the focus is on potential dementia and cognitive impairment, says Dam, but in the future, myAvos will more holistically target all preventable chronic illnesses. But dementia is one of the major causes of disability among older people around the world and people living with it is expected to triple by 2050.

“If we can empower people with health literacy, we really believe we can prevent chronic disease,” says Dam. “Forty percent of dementia is preventable. A lot of these chronic diseases are preventable. Even diabetes can be reversible.”

And she points out that the changes that can be made to help cognitive health can affect other systems as well.

“We really want to empower the individuals,” Dam says. “If we can empower people with health literacy, we really believe we can prevent chronic disease.”

And myAvos is the key. The app is based on a subscription model, allowing users full access to a risk calculator, monthly cognitive assessments, personalized lifestyle guidance, and even fun brain games to keep them sharp. It may turn out that a visit with Laura a day will keep the doctor away long into your later years.

Le Dam moved from California to Houston to build her company. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.